Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2015 (2015), Article ID 379287, 11 pages
http://dx.doi.org/10.1155/2015/379287
Research Article

Alteration of Mevalonate Pathway in Proliferated Vascular Smooth Muscle from Diabetic Mice: Possible Role in High-Glucose-Induced Atherogenic Process

1Department of Endocrinology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, China
2Department of Respirology, Zhejiang Provincial People’s Hospital, Hangzhou 310014, China
3Institute of Cardiology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, China
4Department of Cardiology, Zhejiang Hospital, Hangzhou 310003, China

Received 25 January 2015; Revised 17 March 2015; Accepted 17 March 2015

Academic Editor: Bernard Portha

Copyright © 2015 Guo-Ping Chen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. D. Nickerson and S. Dutta, “Diabetic complications: current challenges and opportunities,” Journal of Cardiovascular Translational Research, vol. 5, no. 4, pp. 375–379, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. A. M. Schmidt, “Recent highlights of ATVB: diabetes mellitus,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 34, no. 5, pp. 954–958, 2014. View at Publisher · View at Google Scholar · View at Scopus
  3. K. E. Porter and K. Riches, “The vascular smooth muscle cell: a therapeutic target in type 2 diabetes?” Clinical Science, vol. 125, no. 4, pp. 167–182, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Rudijanto, “The role of vascular smooth muscle cells on the pathogenesis of atherosclerosis,” Acta Medica Indonesiana, vol. 39, no. 2, pp. 86–93, 2007. View at Google Scholar · View at Scopus
  5. A. Chait and K. E. Bornfeldt, “Diabetes and atherosclerosis: is there a role for hyperglycemia?” Journal of Lipid Research, vol. 50, supplement, pp. S335–S339, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. J. L. Goldstein and M. S. Brown, “Regulation of the mevalonate pathway,” Nature, vol. 343, no. 6257, pp. 425–430, 1990. View at Publisher · View at Google Scholar · View at Scopus
  7. I. Buhaescu and H. Izzedine, “Mevalonate pathway: a review of clinical and therapeutical implications,” Clinical Biochemistry, vol. 40, no. 9-10, pp. 575–584, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. L. Li, S.-J. Hu, H.-T. Dong, L. Kang, N.-Y. Chen, and Y.-Q. Fang, “Alterations in gene expression of series key enzymes in mevalonic acid pathway detected by RNA array in spontaneously hypertensive rats,” Chinese Journal of Pathophysiology, vol. 24, no. 1, pp. 54–59, 2008. View at Google Scholar
  9. G.-P. Chen, L. Yao, X. Lu, L. Li, and S.-J. Hu, “Tissue-specific effects of atorvastatin on 3-hydroxy-3-methylglutaryl- coenzyme A reductase expression and activity in spontaneously hypertensive rats,” Acta Pharmacologica Sinica, vol. 29, no. 10, pp. 1181–1186, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. J. Han, D.-M. Jiang, C.-Q. Du, and S.-J. Hu, “Alteration of enzyme expressions in mevalonate pathway—possible role for cardiovascular remodeling in spontaneously hypertensive rats,” Circulation Journal, vol. 75, no. 6, pp. 1409–1417, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. C.-Q. Du, L. Yang, J. Yang et al., “Inhibition of farnesyl pyrophosphate synthase prevents norepinephrine-induced fibrotic responses in vascular smooth muscle cells from spontaneously hypertensive rats,” Hypertension Research, vol. 37, no. 1, pp. 26–34, 2014. View at Publisher · View at Google Scholar · View at Scopus
  12. D. Vicent, E. Maratos-Flier, and C. R. Kahn, “The branch point enzyme of the mevalonate pathway for protein prenylation is overexpressed in the ob/ob mouse and induced by adipogenesis,” Molecular and Cellular Biology, vol. 20, no. 6, pp. 2158–2166, 2000. View at Publisher · View at Google Scholar · View at Scopus
  13. K.-K. Wu and Y. Huan, “Diabetic atherosclerosis mouse models,” Atherosclerosis, vol. 191, no. 2, pp. 241–249, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. X. Shen and K. E. Bornfeldt, “Mouse models for studies of cardiovascular complications of type 1 diabetes,” Annals of the New York Academy of Sciences, vol. 1103, pp. 202–217, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. O. J. Müller, H. A. Katus, and J. Backs, “Macrovascular disease in diabetes: is the mouse a suitable model?” Experimental and Clinical Endocrinology and Diabetes, vol. 120, no. 4, pp. 194–196, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. F. B. Mehrhof, R. Schmidt-Ullrich, R. Dietz, and C. Scheidereit, “Regulation of vascular smooth muscle cell proliferation: role of NF-kappaB revisted,” Circulation Research, vol. 96, no. 9, pp. 958–964, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. G.-P. Chen, Y. Ye, L. Li, Y. Yang, A.-B. Qian, and S.-J. Hu, “Endothelium-independent vasorelaxant effect of sodium ferulate on rat thoracic aorta,” Life Sciences, vol. 84, no. 3-4, pp. 81–88, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. V. Pallottini, C. Martini, G. Cavallini et al., “Age-related HMG-CoA reductase deregulation depends on ROS-induced p38 activation,” Mechanisms of Ageing and Development, vol. 128, no. 11-12, pp. 688–695, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. M. K. Dhar, A. Koul, and S. Kaul, “Farnesyl pyrophosphate synthase: a key enzyme in isoprenoid biosynthetic pathway and potential molecular target for drug development,” New Biotechnology, vol. 30, no. 2, pp. 114–123, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. A. P. Kourounakis, M. G. Katselou, A. N. Matralis, E. M. Ladopoulou, and E. Bavavea, “Squalene synthase inhibitors: an update on the search for new antihyperlipidemic and antiatherosclerotic agents,” Current Medicinal Chemistry, vol. 18, no. 29, pp. 4418–4439, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. A. J. Wiemer, D. F. Wiemer, and R. J. Hohl, “Geranylgeranyl diphosphate synthase: an emerging therapeutic target,” Clinical Pharmacology and Therapeutics, vol. 90, no. 6, pp. 804–812, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. J. Park, A. N. Matralis, A. M. Berghuis, and Y. S. Tsantrizos, “Human isoprenoid synthase enzymes as therapeutic targets,” Frontiers in Chemistry, vol. 2, p. 50, 2014. View at Publisher · View at Google Scholar
  23. S. P. Gray and K. Jandeleit-Dahm, “The pathobiology of diabetic vascular complications—cardiovascular and kidney disease,” Journal of Molecular Medicine, vol. 92, no. 5, pp. 441–452, 2014. View at Publisher · View at Google Scholar · View at Scopus
  24. M. A. Potenza, C. Nacci, S. Gagliardi, and M. Montagnani, “Cardiovascular complications in diabetes: lessons from animal models,” Current Medicinal Chemistry, vol. 18, no. 12, pp. 1806–1819, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. G. Orasanu and J. Plutzky, “The pathologic continuum of diabetic vascular disease,” Journal of the American College of Cardiology, vol. 53, supplement, no. 5, pp. S35–S42, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. V. V. Kunjathoor, D. L. Wilson, and R. C. LeBoeuf, “Increased atherosclerosis in streptozotocin-induced diabetic mice,” The Journal of Clinical Investigation, vol. 97, no. 7, pp. 1767–1773, 1996. View at Publisher · View at Google Scholar · View at Scopus
  27. P. Otero, B. Bonet, E. Herrera, and A. Rabano, “Development of atherosclerosis in the diabetic BALB/c mice: prevention with vitamin E administration,” Atherosclerosis, vol. 182, no. 2, pp. 259–265, 2005. View at Publisher · View at Google Scholar · View at Scopus
  28. J. Chen, M. Dai, and Y. Wang, “Paeonol inhibits proliferation of vascular smooth muscle cells stimulated by high glucose via Ras-Raf-ERK1/2 signaling pathway in coculture model,” Evidence-Based Complementary and Alternative Medicine, vol. 2014, Article ID 484269, 9 pages, 2014. View at Publisher · View at Google Scholar
  29. Y. Mebratu and Y. Tesfaigzi, “How ERK1/2 activation controls cell proliferation and cell death: is subcellular localization the answer?” Cell Cycle, vol. 8, no. 8, pp. 1168–1175, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. Y. Zhao, J. Liu, L. Li, L. Liu, and L. Wu, “Role of Ras/PKCζ/MEK/ERK1/2 signaling pathway in angiotensin II-induced vascular smooth muscle cell proliferation,” Regulatory Peptides, vol. 128, no. 1, pp. 43–50, 2005. View at Publisher · View at Google Scholar
  31. D. Popov, M. Nemecz, M. Dumitrescu, A. Georgescu, and F. D. Böhmer, “Long-term high glucose concentration influences Akt, ERK1/2, and PTP1B protein expression in human aortic smooth muscle cells,” Biochemical and Biophysical Research Communications, vol. 388, no. 1, pp. 51–55, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. K. Ishiko, T. Sakoda, T. Akagami et al., “Hyperglycemia induced cell growth and gene expression via the serum response element through rhoa and rho-kinase in vascular smooth muscle cells,” Preparative Biochemistry & Biotechnology, vol. 40, no. 2, pp. 139–151, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. N. Sawada, Y. Li, and J. K. Liao, “Novel aspects of the roles of Rac1 GTPase in the cardiovascular system,” Current Opinion in Pharmacology, vol. 10, no. 2, pp. 116–121, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. L.-H. Zhu, L. Wang, D. Wang et al., “Puerarin attenuates high-glucose and diabetes-induced vascular smooth muscle cell proliferation by blocking PKCbeta2/Rac1-dependent signaling,” Free Radical Biology & Medicine, vol. 48, no. 4, pp. 471–482, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. S. J. McTaggart, “Isoprenylated proteins,” Cellular and Molecular Life Sciences, vol. 63, no. 3, pp. 255–267, 2006. View at Publisher · View at Google Scholar · View at Scopus
  36. R. Roskoski Jr., “Protein prenylation: a pivotal posttranslational process,” Biochemical and Biophysical Research Communications, vol. 303, no. 1, pp. 1–7, 2003. View at Publisher · View at Google Scholar · View at Scopus
  37. P. J. Casey, “Protein lipidation in cell signaling,” Science, vol. 268, no. 5208, pp. 221–225, 1995. View at Publisher · View at Google Scholar · View at Scopus
  38. S. J. Nicholls, C. M. Ballantyne, P. J. Barter et al., “Effect of two intensive statin regimens on progression of coronary disease,” The New England Journal of Medicine, vol. 365, no. 22, pp. 2078–2087, 2011. View at Publisher · View at Google Scholar · View at Scopus
  39. B. Stegman, R. Puri, L. Cho et al., “High-intensity statin therapy alters the natural history of diabetic coronary atherosclerosis: insights from SATURN,” Diabetes Care, vol. 37, no. 11, pp. 3114–3120, 2014. View at Publisher · View at Google Scholar
  40. J. K. Liao and U. Laufs, “Pleiotropic effects of statins,” Annual Review of Pharmacology and Toxicology, vol. 45, pp. 89–118, 2005. View at Publisher · View at Google Scholar · View at Scopus
  41. U. Laufs and J. K. Liao, “Direct vascular effects of HMG-CoA reductase inhibitors,” Trends in Cardiovascular Medicine, vol. 10, no. 4, pp. 143–148, 2000. View at Publisher · View at Google Scholar · View at Scopus
  42. N. Sattar, D. Preiss, H. M. Murray et al., “Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials,” The Lancet, vol. 375, no. 9716, pp. 734–742, 2010. View at Publisher · View at Google Scholar
  43. D. Preiss, S. R. K. Seshasai, P. Welsh et al., “Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis,” The Journal of the American Medical Association, vol. 305, no. 24, pp. 2556–2564, 2011. View at Publisher · View at Google Scholar · View at Scopus
  44. D. I. Swerdlow, D. Preiss, K. B. Kuchenbaecker et al., “HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials,” The Lancet, vol. 385, no. 9965, pp. 351–361, 2015. View at Publisher · View at Google Scholar
  45. B. D. Henriksbo, T. C. Lau, J. F. Cavallari et al., “luvastatin causes NLRP3 inflammasome-mediated adipose insulin resistance,” Diabetes, vol. 63, no. 11, pp. 3742–3747, 2014. View at Publisher · View at Google Scholar
  46. R. G. G. Russell, “Bisphosphonates: the first 40 years,” Bone, vol. 49, no. 1, pp. 2–19, 2011. View at Publisher · View at Google Scholar · View at Scopus
  47. M. Bevilacqua, L. J. Dominguez, S. Rosini, and M. Barbagallo, “Bisphosphonates and atherosclerosis: why?” Lupus, vol. 14, no. 9, pp. 773–779, 2005. View at Publisher · View at Google Scholar · View at Scopus
  48. R. Ylitalo, “Bisphosphonates and atherosclerosis,” General Pharmacology: The Vascular System, vol. 35, no. 6, pp. 287–296, 2000. View at Publisher · View at Google Scholar · View at Scopus
  49. L. Wu, L. Zhu, W.-H. Shi, J. Zhang, D. Ma, and B. Yu, “Zoledronate inhibits the proliferation, adhesion and migration of vascular smooth muscle cells,” European Journal of Pharmacology, vol. 602, no. 1, pp. 124–131, 2009. View at Publisher · View at Google Scholar · View at Scopus